NFKB1 and metabolic dysfunction-associated steatotic liver disease: USP13 interacts with TAK1, inhibits TAK1 activation by removing ubiquitination of TAK1, and subsequently inhibits the NF-κB & MAPK signaling pathway activation (Fig. 9), thereby treating NAFLD as a latent molecular target.